Effects of Exercise on sRAGE Levels and Cardiometabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized Controlled Trial

被引:84
|
作者
Choi, Kyung Mook [1 ]
Han, Kyung Ah [4 ]
Ahn, Hee Jung [5 ]
Hwang, Soon Young [2 ,3 ]
Hong, Ho Cheol [1 ]
Choi, Hae Yoon [1 ]
Yang, Sae Jeong [1 ]
Yoo, Hye Jin [1 ]
Baik, Sei Hyun [1 ]
Choi, Dong Seop [1 ]
Min, Kyung Wan [4 ]
机构
[1] Korea Univ, Div Endocrinol & Metab, Seoul 136701, South Korea
[2] Korea Univ, Coll Med, Dept Internal Med, Seoul 136701, South Korea
[3] Korea Univ, Coll Med, Dept Biostat, Seoul 136701, South Korea
[4] Eulji Hosp, Dept Internal Med, Seoul 139711, South Korea
[5] Eulji Hosp, Ctr Diabet, Seoul 139711, South Korea
来源
基金
新加坡国家研究基金会;
关键词
GLYCATION END-PRODUCTS; ENDOGENOUS SECRETORY RAGE; C-REACTIVE PROTEIN; SOLUBLE RECEPTOR; VASCULAR INFLAMMATION; ENDOTHELIAL FUNCTION; GLYCEMIC CONTROL; PLASMA-LEVELS; ATHEROSCLEROSIS; ASSOCIATION;
D O I
10.1210/jc.2012-1951
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Low levels of soluble receptor for advanced glycation end-products (sRAGE) have been linked to systemic inflammation and vascular complications in patients with type 2 diabetes mellitus (T2DM). Objective: We examined the effects of exercise on sRAGE and its association with diverse cardiometabolic risk factors and indicators of atherosclerosis in patients with T2DM. Design, Setting, and Participants: Seventy-five patients with T2DM were randomized into a control group and an aerobic exercise group (60 min at moderate intensity, five times/wk for 12 wk). Main Outcome Measures: We evaluated sRAGE, energy expenditure, dietary energy intake, cardiorespiratory fitness, inflammatory markers, visceral fat area, pulse-wave velocity, and flow-mediated dilatation. Results: Baseline sRAGE concentrations were independently associated with age, glycated hemoglobin, glucose, triglyceride, and high-density lipoprotein cholesterol levels (R-2 = 0.244). After 12 wk of exercise training, the exercise group showed significantly decreased body weight, waist circumference, blood pressure, glycated hemoglobin, apolipoprotein B, and free fatty acid levels. Concurrently, cardiorespiratory fitness assessed by oxygen uptake at anaerobic threshold was improved, and body fat percentage and visceral fat area were significantly decreased in the exercise group, although pulse-wave velocity and flow-mediated dilatation were not changed. Furthermore, sRAGE levels were increased and high-sensitivity C-reactive protein levels were decreased in the exercise group but not in the control group. PercentchangeofsRAGElevelwasnegatively correlated with that of high-sensitivity C-reactive protein during the study period (r = -0.27; P = 0.019). Conclusions: Aerobic exercise increases sRAGE levels along with improvement of various cardiometabolic risk factors in patients with T2DM. (J Clin Endocrinol Metab 97: 3751-3758, 2012)
引用
收藏
页码:3751 / 3758
页数:8
相关论文
共 50 条
  • [21] Effect of Ziziphus jujube on cardiometabolic factors and systemic inflammation in type 2 diabetic patients: A randomized controlled trial
    Farhadnejad, Hossein
    Asghari, Golaleh
    Hedayati, Mehdi
    Sahranavard, Shamim
    Teymoori, Farshad
    Mirmiran, Parvin
    Azizi, Fereidoun
    CLINICAL NUTRITION ESPEN, 2022, 49 : 53 - 60
  • [22] Effect of Exercise on Blood Pressure in Type 2 Diabetes: A Randomized Controlled Trial
    Dobrosielski, Devon A.
    Gibbs, Bethany Barone
    Ouyang, Pamela
    Bonekamp, Susanne
    Clark, Jeanne M.
    Wang, Nae-Yuh
    Silber, Harry A.
    Shapiro, Edward P.
    Stewart, Kerry J.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2012, 27 (11) : 1453 - 1459
  • [23] Effect of Exercise on Blood Pressure in Type 2 Diabetes: A Randomized Controlled Trial
    Devon A. Dobrosielski
    Bethany Barone Gibbs
    Pamela Ouyang
    Susanne Bonekamp
    Jeanne M. Clark
    Nae-Yuh Wang
    Harry A. Silber
    Edward P. Shapiro
    Kerry J. Stewart
    Journal of General Internal Medicine, 2012, 27 : 1453 - 1459
  • [24] Effects of Stress Reduction on Cardiovascular Risk Factors in Type 2 Diabetes Patients with Early Kidney Disease - Results of a Randomized Controlled Trial (HEIDIS)
    Kopf, S.
    Oikonomou, D.
    Hartmann, M.
    Feier, F.
    Faude-Lang, V.
    Morcos, M.
    Haering, H. -U.
    Herzog, W.
    Bierhaus, A.
    Humpert, P. M.
    Nawroth, P. P.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (06) : 341 - 349
  • [25] Ipragliflozin Improved Cardiometabolic Risk Factors in Japanese Patients with Type 2 Diabetes: A Pooled Analysis of Six Randomized, Placebo-Controlled Trials
    Kashiwagi, Atsunori
    Yoshida, Satoshi
    Nakamura, Ichiro
    Akiyama, Noriko
    Kazuta, Kenichi
    Ueyama, Eiji
    Takahashi, Hideyuki
    Kosakai, Yoshinori
    Kawamuki, Kosei
    DIABETES, 2016, 65 : A287 - A288
  • [26] Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial
    Chuengsamarn, Somlak
    Rattanamongkolgul, Suthee
    Phonrat, Benjaluck
    Tungtrongchitr, Rungsunn
    Jirawatnotai, Siwanon
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2014, 25 (02): : 144 - 150
  • [27] Weight loss, exercise or both and cardiometabolic risk factors in obese older adults: results of a randomized controlled trial
    Bouchonville, M.
    Armamento-Villareal, R.
    Shah, K.
    Napoli, N.
    Sinacore, D. R.
    Qualls, C.
    Villareal, D. T.
    INTERNATIONAL JOURNAL OF OBESITY, 2014, 38 (03) : 423 - 431
  • [28] Weight loss, exercise or both and cardiometabolic risk factors in obese older adults: results of a randomized controlled trial
    M Bouchonville
    R Armamento-Villareal
    K Shah
    N Napoli
    D R Sinacore
    C Qualls
    D T Villareal
    International Journal of Obesity, 2014, 38 : 423 - 431
  • [29] The effect of hormone replacement therapy on cardiovascular risk factors in type 2 diabetes - A randomized controlled trial
    Manning, PJ
    Allum, A
    Jones, S
    Sutherland, WHF
    Williams, SM
    ARCHIVES OF INTERNAL MEDICINE, 2001, 161 (14) : 1772 - 1776
  • [30] Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial
    Michael Roden
    Ludwig Merker
    Anita Vedel Christiansen
    Flavien Roux
    Afshin Salsali
    Gabriel Kim
    Peter Stella
    Hans J. Woerle
    Uli C. Broedl
    Cardiovascular Diabetology, 14